Tag: Nabil Shabshab

 GOLETA, Calif. – Inogen’s new strategy is taking longer than expected, says CEO Nabil Shabshab, resulting in “disappointing” financial results for the second quarter, especially for its direct-to-consumer sales channel.  The company reported $26.8 million in DTC sales for the quarter compared to $40.6 million for the same period last year.  “While we have made progress with the execution of our commercial strategy, we are disappointed with the performance...

GOLETA, Calif. – Inogen’s 10.2% decrease in total revenues for the first quarter of 2023 was impacted, in part, by HME provider customers tightening their belts, but the company is making progress winning them over with its value proposition, says CEO Nabil Shabshab.  The company reported sales revenue of $55.8 million for the first quarter of 2023 compared to $67.4 million for the same period in 2022, about a 17% decrease.  “There were some challenges in the business-to-business...

GOLETA, Calif. – Inogen is prioritizing its prescriber channel as it seeks to drive productivity and profitability, and transform itself into “a med tech company that has a global footprint and can go beyond COPD,” says CEO Nabil Shabshab.  Compared to the direct-to-consumer channel, which requires significant investments in advertising and a salesforce to generate and convert leads, the prescriber channel has a higher return on investment, he says.  “(The...

GOLETA, Cailf. – Two major factors contributed to Inogen’s 13.2% increase in revenue in the third quarter: The company remediated “the significant portion of its backlog,” and it made “excellent progress” with its prescriber strategy, says President and CEO Nabil Shabshab.    Shabshab declined to detail the size of the backlog of orders in its domestic business-to-business channel, but Inogen recorded $42.5 million in sales for the channel in the third...

GOLETA, Calif. – Inogen has reported total revenue of $105.4 million for the third quarter of 2022, a 13.2% increase compared to the same period last year.  Revenue increased primarily due to higher domestic business-to-business sales, as well as continued strength in the rental channel, partially offset by lower international business-to-business and direct-to-consumer sales  “I am pleased with the progress the team has made on our transformational journey,” said...

GOLETA, Calif. – Supply chain challenges, as well as a temporary shutdown at facilities in Texas and California earlier this year, forced Inogen to prioritize available supply in the first quarter of 2022 to its domestic direct-to-consumer and rental channels, contributing to an 83.4% drop in revenues for its business-to-business channel.  “As of early May, we have started shipments to our domestic B2B channel in order to alleviate some of the backlog in our system,”...

GOLETA, Calif. – Inogen reported revenue of $76.4 million for the fourth quarter of 2021, an increase of 3.3% over the same period in 2020, driven by a 23.3% in domestic direct-to-consumer sales to $33 million.  Domestic business-to-business sales in the fourth quarter of 2021 decreased 57.6% to $10.3 million compared to $24.2 million in the fourth quarter of 2020, primarily due to the supply chain constraints that limited product availability in this channel.  Rental revenue...

GOLETA, Calif. – Inogen says its revenues are expected to increase for the fourth quarter of 2021, but a chip shortage has forced the company to temporarily suspend manufacturing operations at its Texas and California locations.  Inogen doesn’t expect to furlough any employees as a result of the suspension, as the company currently anticipates restarting manufacturing at all locations around mid- to late February 2022 based on the information available to date.  For the...

GOLETA, Calif. – Demand is high, but with supply restricted, Inogen is prioritizing POC orders from its direct-to-consumer channel.  That meant it was unable to fulfill some orders from other channels, particularly its domestic business-to-business channel, which saw sales of $22.8 million in the third quarter, down 1.1% from the same period last year.  "Due to supply chain constraints and in an effort to optimize financial results, we intentionally focused our available capacity...

GOLETA, Calif. – Inogen has named Stanislav Glezer, M.D., to the role of CTO responsible for R&D and engineering, medical affairs and regulatory affairs. Glezer, who joined Inogen in June, will remain an executive vice president of the company. He has more than 27 years of experience and has held leadership roles at a variety of medical technology and biotechnology firms, including Becton, Dickinson and Company, Adocia S.A., Novo Nordisk, Inc., and Sanofi S.A. “Since joining Inogen...